News | July 08, 2022
ALPLA acquires Polish packaging manufacturer APON
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Govt committed to supporting pharma companies with industry-friendly policies
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
It is a two dose vaccine to be administered intramuscularly at 28 days apart
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
Subscribe To Our Newsletter & Stay Updated
